retatrutide phase 2 trial obesity nejm 2023 In patients with #obesity, incretin-based therapies such as GLP-1 receptor agonists are reported to result in mean weight reductions of approximately 15 to 20% along with additional health benefits, including decreased cardiovascular Retatrutide Shows 28.3% Weight Loss

Key trials include a 2017 phase 2 study of exenatide showing modest motor improvements, and the 2024 LIXIPARK study demonstrating lixisenatide benefits on motor function

Yes, we give our members Semaglutide (Ozempic), which is taken by injection weekly

If you take insulin or sulfonylureas with GLP-1 therapy, check your blood glucose when experiencing cognitive symptoms, as hypoglycemia can mimic brain fog

US Address Perfect 161 Natoma St, San Francisco, CA 94105

Mathieu C, Dandona P, Gillard P et al (2018) Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 Study): 24-week results from a randomized controlled trial